Citizens Jmp Has Lowered Expectations for Stereotaxis (NYSEAMERICAN:STXS) Stock Price

Stereotaxis (NYSEAMERICAN:STXS) had its price target decreased by stock analysts at Citizens Jmp from $4.00 to $3.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. Citizens Jmp’s price target points to a potential upside of 100.67% from the company’s current price.

A number of other research firms have also recently issued reports on STXS. Citigroup reaffirmed an “outperform” rating on shares of Stereotaxis in a research report on Thursday. TD Cowen lowered their price target on shares of Stereotaxis from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Wednesday, August 12th. Finally, Piper Sandler reissued an “overweight” rating and issued a $3.50 price objective (down from $4.00) on shares of Stereotaxis in a report on Wednesday, May 13th. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Stereotaxis currently has a consensus rating of “Buy” and a consensus target price of $3.50.

Stereotaxis Price Performance

STXS stock traded up $0.04 during midday trading on Thursday, hitting $1.50. The company’s stock had a trading volume of 65,528 shares, compared to its average volume of 601,109. The company’s fifty day moving average price is $1.54 and its 200 day moving average price is $1.80. The stock has a market capitalization of $149.80 million, a P/E ratio of -6.19 and a beta of 1.37. Stereotaxis has a twelve month low of $1.24 and a twelve month high of $3.59.

Stereotaxis (NYSEAMERICAN:STXS) last released its earnings results on Tuesday, August 11th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.05). The business had revenue of $7.67 million for the quarter, compared to analyst estimates of $8.35 million. Stereotaxis had a negative return on equity of 130.84% and a negative net margin of 74.24%. Equities analysts expect that Stereotaxis will post -0.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Stereotaxis

Several hedge funds and other institutional investors have recently modified their holdings of STXS. Deutsche Bank AG lifted its position in shares of Stereotaxis by 10.6% during the fourth quarter. Deutsche Bank AG now owns 51,584 shares of the company’s stock worth $119,000 after purchasing an additional 4,948 shares during the last quarter. Schonfeld Strategic Advisors LLC boosted its holdings in shares of Stereotaxis by 47.0% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 17,801 shares of the company’s stock valued at $41,000 after acquiring an additional 5,692 shares in the last quarter. BNP Paribas Financial Markets raised its position in Stereotaxis by 106.5% in the third quarter. BNP Paribas Financial Markets now owns 11,461 shares of the company’s stock worth $36,000 after acquiring an additional 5,910 shares in the last quarter. Bank of America Corp DE grew its position in Stereotaxis by 12.0% in the third quarter. Bank of America Corp DE now owns 63,114 shares of the company’s stock worth $196,000 after buying an additional 6,742 shares during the last quarter. Finally, Barclays PLC lifted its holdings in shares of Stereotaxis by 4.9% during the fourth quarter. Barclays PLC now owns 150,246 shares of the company’s stock valued at $346,000 after purchasing an additional 7,062 shares during the last quarter. 45.35% of the stock is owned by institutional investors.

About Stereotaxis

Stereotaxis, Inc is a medical device company that develops and commercializes robotic magnetic navigation systems for use in electrophysiology procedures. Its core technology leverages precisely controlled magnetic fields to guide ultra-thin, magnetically enabled catheters through the vascular system, allowing physicians to perform complex cardiac ablation and diagnostic procedures with enhanced precision and stability. This platform aims to reduce procedure times and radiation exposure for both patients and clinical staff.

The company’s flagship offering, the Niobe Magnetic Navigation System, integrates with a variety of catheter types and electrophysiology mapping systems to support treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia.